JMDC (4483) Q1 2027 earnings summary

Executive summary

• Q1 FY2026 revenue rose 18% year-over-year to ¥12,605 million, with EBITDA up 17% to ¥2,663 million, exceeding expectations due to strong Industry demand and early revenue recognition.

• Operating profit increased 17% to ¥1,823 million; profit attributable to owners of parent rose 17% to ¥1,131 million, with basic earnings per share at ¥17.28.

• Both Healthcare - Big Data and Tele-medicine segments contributed to growth, with segment profits up 17% and 22% year-over-year, respectively.

• Growth momentum continued despite a high baseline from the previous year, with no reactionary drop in performance.

• Strategic investments and fixed costs progressed as planned, supporting structural profitability.

Financial highlights

• Consolidated revenue reached ¥12,605 million, up 18% year-over-year; gross profit increased to ¥6,745 million.

• EBITDA was ¥2,663 million, up 17% year-over-year, with a margin of 21%.

• Operating profit rose 17% to ¥1,823 million; profit attributable to owners increased 17% to ¥1,131 million.

• Cash and cash equivalents increased by ¥1,830 million to ¥30,780 million.

• Transaction volume for Industry data utilization grew 26% year-over-year; for Medical Service Providers, up 20%.

Outlook and guidance

• H1 FY2026 revenue forecast is ¥27,100 million, up 17% year-over-year; EBITDA forecast is ¥6,100 million, up 11%.

• Full-year revenue forecast for fiscal year ending March 31, 2027, is ¥60,500 million, up 19.9% year-over-year.

• Operating profit is projected at ¥11,500 million, with profit attributable to owners of parent at ¥7,100 million.

• H1 EBITDA margin expected to temporarily decline to 23% from 24% last year due to strategic investments.

• Full-year guidance maintained, with business performance weighted toward H2.